dm+d

Unassigned

New Medicines

Duchenne muscular dystrophy

Information

New molecular entity
Processa
Processa

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Nov 21No longer listed in company pipeline; assume development discontinued [15].

Category

Potent inhibitor of collagen type I synthesis and collagenase activity
DMD affects about 1 in 3,500 newborn males. There is progressive proximal muscular dystrophy with characteristic pseudohypertrophy of the calves. All patients have symptoms by age 3 years, but diagnosis is often delayed. [2]
Duchenne muscular dystrophy
Oral